Search for: "Myriad Construction, Inc." Results 101 - 120 of 141
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 May 2012, 11:30 am by Lucas A. Ferrara, Esq.
Must possess 3-6 years of Construction/Labor Law 240 Claims experience. [read post]
1 Mar 2012, 6:24 am
In fact, Maine Industrial Tire's 50 employees can't keep up with contracts from big names like John Deere, Bobcat, and Caterpillar, clamoring for the company's solid rubber products used on forklifts and construction equipment. [read post]
22 Oct 2011, 12:30 pm by Steve Bainbridge
A modern version of this rationale can be constructed by building on the burgeoning insights for legal analysis of cognitive psychology and behavioral economics. [read post]
3 Aug 2011, 3:31 am by Marie Louise
Patent and Trademark Office (Holman’s Biotech IP Blog) US: Myriad writes to CAFC on standing issue (Patent Docs) (Patent Docs) (Holman’s Biotech IP Blog) US: In the first 7 months of 2011, the FDA has approved 18 new molecular entity pharmaceutical drugs (and no biologic NMEs) (KEI) US: Embryonic stem cell funding suit dead: Sherley v. [read post]
23 Jun 2011, 1:19 pm by Dan Parlow
Recently, the Ontario Court of Appeal ruled that settlements involving some but not all parties – sometimes called “Mary Carter agreements” – must be immediately disclosed to level the playing field between the remaining parties: Aecon Buildings, a Division of Aecon Construction Group Inc. v. [read post]
23 Jun 2011, 1:19 pm by Dan Parlow
Recently, the Ontario Court of Appeal ruled that settlements involving some but not all parties – sometimes called “Mary Carter agreements” – must be immediately disclosed to level the playing field between the remaining parties: Aecon Buildings, a Division of Aecon Construction Group Inc. v. [read post]
5 Apr 2011, 5:21 am by Stefanie Levine
Myriad argued that the District Court made a claim construction error in that the District Court considered a DNA "sequence" to be data, rather than a physical molecule. [read post]
5 Apr 2011, 5:21 am by Stefanie Levine
Myriad argued that the District Court made a claim construction error in that the District Court considered a DNA "sequence" to be data, rather than a physical molecule. [read post]
4 Feb 2011, 5:52 am by Ashley Moye
The Myriad Genetics’ Breast Cancer Gene Patent Dispute On March 29, 2010, a court in the Southern District of New York invalidated certain patents issued to Myriad Genetics, Inc., relating to the BRCA1 and BRCA2 breast cancer genes on the grounds that the genes were nonpatentable subject matter. [read post]